Skip to main content

Table 3 Comparison of DFS among different chemotherapy groups in patients with low TopIIα expression

From: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer

Chemotherapy regimens Number Median DFS (months) P
Vinorelbine Containing 29 48.16 0.065
  Not containing 88 16.23  
Gemcitabine Containing 39 14.13 0.530
  Not containing 78 22.74  
Docetaxel Containing 33 15.74 0.194
  Not containing 84 22.74  
Paclitaxel Containing 16 22.97 0.990
  Not containing 101 18.76